LIMN (Liminatus Pharma Corp) נזילות מהירה

Liminatus Pharma (LIMN) possesses a narrow development pipeline, which creates a risk of sharp volatility until regulatory approvals are obtained. Growth is driven by successes in developing new intestinal treatments and potential mergers, with the metric standing at 1.14. The price indicator on the GURU.Markets platform chart visualizes the asset's price action. The business relies on creating unique methods for combating tumors to extract long-term profit from patents.

For Liminatus Pharma (LIMN), whose immunotherapy developments do not generate operating cash, the ability to cover short-term obligations without liquidating inventory is critical. This level of strict solvency, recorded as 1.14, measures liquidity through the sum of cash and accounts receivable, determining the company's resilience to cash flow gaps between capital raising rounds.